About
Josh Spiegel is a healthcare and technology executive focused on AI-enabled clinical research and drug-development strategy. He was appointed President of NetraMark Corp. on July 13, 2022, and company materials describe him as having more than 25 years of experience in finance and corporate strategy, including prior roles at VeraSci, Prevail Therapeutics, Cypress Associates, and CIBC World Markets. His work sits at the intersection of biotech, clinical trials, and commercial strategy rather than formal investing.
Areas of interest
biotechhealthtechartificial intelligenceclinical trialspharmaceutical R&DoncologyCNS disorderscorporate strategyhealthcare finance